Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 4 | 2021 | 239 | 1.410 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 50 | 1.010 |
Why?
|
| Ohio | 6 | 2021 | 54 | 0.830 |
Why?
|
| Decision Making | 1 | 2023 | 180 | 0.780 |
Why?
|
| Bayes Theorem | 7 | 2023 | 67 | 0.760 |
Why?
|
| Patient Admission | 2 | 2019 | 53 | 0.720 |
Why?
|
| Research Design | 2 | 2023 | 286 | 0.680 |
Why?
|
| Population Surveillance | 1 | 2019 | 119 | 0.650 |
Why?
|
| Humans | 37 | 2023 | 29093 | 0.540 |
Why?
|
| Data Collection | 1 | 2015 | 163 | 0.530 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 366 | 0.520 |
Why?
|
| Adolescent | 11 | 2021 | 3254 | 0.500 |
Why?
|
| Adult | 17 | 2022 | 8420 | 0.460 |
Why?
|
| Male | 28 | 2023 | 17807 | 0.440 |
Why?
|
| Female | 28 | 2023 | 18164 | 0.430 |
Why?
|
| Middle Aged | 17 | 2022 | 10829 | 0.430 |
Why?
|
| Coronary Disease | 3 | 2022 | 200 | 0.400 |
Why?
|
| Hydrocortisone | 2 | 2021 | 61 | 0.380 |
Why?
|
| Young Adult | 8 | 2019 | 2402 | 0.370 |
Why?
|
| Length of Stay | 3 | 2019 | 292 | 0.360 |
Why?
|
| Upper Extremity | 2 | 2019 | 52 | 0.330 |
Why?
|
| Blood Glucose | 3 | 2020 | 466 | 0.330 |
Why?
|
| Bacterial Infections | 2 | 2018 | 42 | 0.310 |
Why?
|
| Aged | 14 | 2021 | 9487 | 0.290 |
Why?
|
| Stroke | 3 | 2022 | 545 | 0.290 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 430 | 0.290 |
Why?
|
| African Americans | 3 | 2021 | 1373 | 0.250 |
Why?
|
| Prevalence | 3 | 2023 | 896 | 0.240 |
Why?
|
| Hepatitis C | 1 | 2023 | 38 | 0.240 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 37 | 0.230 |
Why?
|
| Substance-Related Disorders | 1 | 2023 | 113 | 0.220 |
Why?
|
| Hospitals, Pediatric | 2 | 2019 | 45 | 0.210 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 9 | 0.210 |
Why?
|
| Retrospective Studies | 8 | 2020 | 3111 | 0.200 |
Why?
|
| Prognosis | 3 | 2019 | 1362 | 0.190 |
Why?
|
| Child | 7 | 2020 | 2219 | 0.190 |
Why?
|
| Advance Care Planning | 1 | 2020 | 10 | 0.190 |
Why?
|
| Video Games | 1 | 2019 | 5 | 0.180 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2019 | 4 | 0.180 |
Why?
|
| Acute Disease | 2 | 2018 | 239 | 0.180 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2019 | 9 | 0.180 |
Why?
|
| Allostasis | 1 | 2019 | 11 | 0.180 |
Why?
|
| Capital Punishment | 1 | 2019 | 1 | 0.180 |
Why?
|
| Adiposity | 1 | 2021 | 191 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2022 | 449 | 0.170 |
Why?
|
| Aldosterone | 1 | 2019 | 28 | 0.170 |
Why?
|
| Methicillin Resistance | 1 | 2019 | 13 | 0.170 |
Why?
|
| Off-Label Use | 1 | 2019 | 11 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 29 | 0.170 |
Why?
|
| Sodium Channel Blockers | 1 | 2018 | 7 | 0.170 |
Why?
|
| HIV Infections | 1 | 2023 | 335 | 0.170 |
Why?
|
| Myotonic Disorders | 1 | 2018 | 3 | 0.170 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 49 | 0.170 |
Why?
|
| Lethargy | 1 | 2018 | 2 | 0.170 |
Why?
|
| Anaphylaxis | 1 | 2019 | 11 | 0.170 |
Why?
|
| Consciousness Disorders | 1 | 2018 | 7 | 0.170 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2018 | 6 | 0.170 |
Why?
|
| Exercise Movement Techniques | 1 | 2018 | 3 | 0.170 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 45 | 0.170 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 37 | 0.170 |
Why?
|
| Cohort Studies | 5 | 2022 | 1687 | 0.170 |
Why?
|
| Muscular Diseases | 1 | 2018 | 19 | 0.170 |
Why?
|
| Paresis | 1 | 2018 | 10 | 0.170 |
Why?
|
| Child Abuse | 1 | 2019 | 26 | 0.170 |
Why?
|
| Parkinson Disease | 1 | 2019 | 68 | 0.170 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 6 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 172 | 0.170 |
Why?
|
| Foot | 1 | 2018 | 40 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 24 | 0.170 |
Why?
|
| Motor Neurons | 1 | 2018 | 53 | 0.170 |
Why?
|
| Office Visits | 1 | 2019 | 71 | 0.160 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 57 | 0.160 |
Why?
|
| Age Factors | 5 | 2019 | 1108 | 0.160 |
Why?
|
| Child, Preschool | 5 | 2019 | 1167 | 0.160 |
Why?
|
| Fever | 1 | 2018 | 56 | 0.160 |
Why?
|
| Pediatrics | 1 | 2020 | 132 | 0.160 |
Why?
|
| Heart Diseases | 1 | 2019 | 97 | 0.160 |
Why?
|
| Exercise Test | 1 | 2019 | 194 | 0.160 |
Why?
|
| Muscle Contraction | 1 | 2018 | 114 | 0.160 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 720 | 0.160 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 9 | 0.160 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2017 | 6 | 0.160 |
Why?
|
| Dermatomyositis | 1 | 2017 | 19 | 0.160 |
Why?
|
| Myotonia Congenita | 1 | 2017 | 1 | 0.160 |
Why?
|
| United States | 3 | 2021 | 3630 | 0.160 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 18 | 0.150 |
Why?
|
| Residence Characteristics | 1 | 2019 | 181 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 39 | 0.150 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 157 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2019 | 2019 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2022 | 693 | 0.140 |
Why?
|
| Depression | 1 | 2019 | 380 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 339 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 173 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 103 | 0.130 |
Why?
|
| Time Factors | 3 | 2019 | 2001 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 494 | 0.120 |
Why?
|
| Ribonucleases | 1 | 2012 | 4 | 0.110 |
Why?
|
| Proteus mirabilis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 816 | 0.110 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2012 | 5 | 0.110 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 43 | 0.110 |
Why?
|
| Organogenesis | 1 | 2012 | 15 | 0.110 |
Why?
|
| Infant | 3 | 2019 | 969 | 0.100 |
Why?
|
| Skin Tests | 1 | 2011 | 15 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 1013 | 0.100 |
Why?
|
| Risk Factors | 4 | 2019 | 3531 | 0.100 |
Why?
|
| Hypersensitivity | 1 | 2011 | 25 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 863 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 2012 | 164 | 0.090 |
Why?
|
| Electromyography | 2 | 2018 | 58 | 0.080 |
Why?
|
| Hand Strength | 2 | 2018 | 85 | 0.080 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 41 | 0.080 |
Why?
|
| Urinary Tract Infections | 2 | 2018 | 36 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 1356 | 0.080 |
Why?
|
| Sex Factors | 2 | 2019 | 631 | 0.080 |
Why?
|
| Accidental Falls | 2 | 2019 | 204 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 637 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2018 | 469 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2019 | 55 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 1119 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 3717 | 0.060 |
Why?
|
| Appalachian Region | 1 | 2023 | 16 | 0.060 |
Why?
|
| Massachusetts | 1 | 2023 | 28 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2023 | 97 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2108 | 0.060 |
Why?
|
| Homosexuality, Male | 1 | 2023 | 73 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2023 | 263 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 38 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 726 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 58 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 163 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 171 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2021 | 89 | 0.050 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 61 | 0.050 |
Why?
|
| Saliva | 1 | 2020 | 36 | 0.050 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 44 | 0.050 |
Why?
|
| Adiponectin | 1 | 2021 | 103 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 43 | 0.050 |
Why?
|
| Algorithms | 1 | 2023 | 462 | 0.050 |
Why?
|
| Hemiplegia | 1 | 2019 | 12 | 0.050 |
Why?
|
| Fasting | 1 | 2020 | 93 | 0.050 |
Why?
|
| Documentation | 1 | 2020 | 32 | 0.050 |
Why?
|
| Mice | 2 | 2018 | 2368 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3099 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 24 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2019 | 27 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 17 | 0.040 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2019 | 3 | 0.040 |
Why?
|
| Stiff-Person Syndrome | 1 | 2018 | 1 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2019 | 96 | 0.040 |
Why?
|
| Myelin Proteins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 19 | 0.040 |
Why?
|
| Toes | 1 | 2018 | 16 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2018 | 11 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 47 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 96 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 4 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2018 | 39 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 211 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 77 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 274 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 369 | 0.040 |
Why?
|
| Neuromuscular Junction | 1 | 2018 | 67 | 0.040 |
Why?
|
| Poverty | 1 | 2019 | 99 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2019 | 110 | 0.040 |
Why?
|
| Triage | 1 | 2019 | 65 | 0.040 |
Why?
|
| Animals | 3 | 2018 | 7297 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 62 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2019 | 168 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 249 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 273 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2017 | 9 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 220 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 109 | 0.040 |
Why?
|
| Action Potentials | 1 | 2018 | 174 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2017 | 26 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 787 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 709 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 45 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 493 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2016 | 14 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2019 | 598 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 572 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 148 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 355 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 285 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 167 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 711 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2017 | 186 | 0.040 |
Why?
|
| Pain | 1 | 2018 | 282 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2016 | 169 | 0.040 |
Why?
|
| Comorbidity | 1 | 2017 | 540 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 332 | 0.030 |
Why?
|
| Obesity | 1 | 2022 | 1063 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 412 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 980 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1131 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 641 | 0.030 |
Why?
|
| Heart Failure | 1 | 2019 | 568 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2012 | 14 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 95 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2012 | 4 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 248 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 51 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2012 | 73 | 0.030 |
Why?
|
| Urothelium | 1 | 2012 | 51 | 0.030 |
Why?
|
| Poaceae | 1 | 2011 | 1 | 0.030 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2011 | 1 | 0.030 |
Why?
|
| Pyroglyphidae | 1 | 2011 | 1 | 0.030 |
Why?
|
| Antigens, Plant | 1 | 2011 | 3 | 0.030 |
Why?
|
| Trees | 1 | 2011 | 2 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 1305 | 0.030 |
Why?
|
| Organ Size | 1 | 2012 | 196 | 0.030 |
Why?
|
| Allergens | 1 | 2011 | 16 | 0.030 |
Why?
|
| Gene Expression | 1 | 2012 | 332 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 130 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 422 | 0.020 |
Why?
|